Van der Zwet K, de Kovel M, Motwani J, Van Geet C, Nolan B, Glosli H, Escuriola Ettingshausen C, Königs C, Kenet G, Fischer K, PedNet Study Group.

Bleeding control improves after switching to emicizumab: Real-world experience of 177 children in the PedNet registry.

Fischer K, Kenet G, Kurnik K, Carcao M, Oldenburg J, Stamm-Mikkelsen T, Cid Haro AR, Koskenvuo M, Blatny J, Königs C, PedNet Study Group.

Determinants of bleeding before and during immune tolerance in 222 boys with severe hemophilia A and inhibitors >5 BU.


G. Andersson N, Labarque V, Kartal-Kaess M, Pinto F, S. Mikkelsen T, Ljung R, PedNet Study Group.

Factor VIII genotype and the risk of developing high-responding or low-responding inhibitors in severe hemophilia A: data from the PedNet Hemophilia Cohort of 1,202 children. 

Ranta S, Motwani J, Blatny J, Bührlen M, Carcao M, Chambost H, Escuriola C, Fischer K, Kartal-Kaess M, de Kovel M, Kenet G, Male C, Nolan B, d’Oiron R, Olivieri M, Zapotocka E, G. Andersson N, Königs C.

Dilemmas on emicizumab in children with haemophilia A: A survey of strategies from PedNet centres.

Labarque V, Mancuso ME, Kartal-Kaess M, Ljung R, S. Mikkelsen T, G. Andersson N.

F8/F9 variants in the population-based PedNet Registry cohort compared with locus-specific genetic databases of the European Association for Haemophilia and Allied Disorders and the Centers for Disease Control and Prevention Hemophilia A or Hemophilia B Mutation Project.

Fischer K, Carcao M, Male C, Ranta S, Pergantou H, Kenet G, Kartal-Kaess M, Königs C, Carvalho M, Alvarez MT, Brakenhoff T, Chambost H, van den Berg HM.

Different inhibitor incidence for individual factor VIII concentrates in 1076 PUPS with severe hemophilia A: data from the PedNet cohort.
Supplemental material:


Ljung R, de Kovel M, van den Berg HM, on behalf of the PedNet study group.

Primary prophylaxis in children with severe haemophilia A and B – Implementation over the last 20 years as illustrated in real-world data in the PedNet cohorts

Schmidt DE, Michalopoulou A, Fischer K, Motwani J, G. Andersson N, Pergantou H, Ranta S, the PedNet Study group.

Long-term joint outcome in adolescents with moderate or severe haemophilia A


Álvarez-Román MT, Kurnik K, the PedNet study group.

Care for children with haemophilia during COVID-19: Data of the PedNet study group

Koskenvuo M, Mäkipernaa A, Nolan B, Kobelt R, Ranta S.

Correction of haemostasis can be reduced to four days for CVAD implantation in severe haemophilia A patients: Data from the PedNet study group


Andersson NG, Labarque V, Letelier A, Mancuso ME, Bührlen M, Fischer K, Kartal-Kaess M, Koskenvuo M, Mikkelsen T, Ljung R, the PedNet study group.

Novel F8 and F9 gene variants from the PedNet hemophilia registry classified according to ACMG/AMP guidelines

Andersson NG, Wu R, Carcao M, Claeyssens-Donadel S, Kobelt R, Liesner R, Mäkipernaa A, Ranta S, Ljung R, the ICH study group.

Long-term follow-up of neonatal intracranial haemorrhage in children with severe Haemophilia

Jonker CJ, Oude Rengerink K, Hoes AW, Mol PGM, van den Berg HM.

Inhibitor development in previously untreated patients with severe haemophilia: A comparison of included patients and outcomes between a clinical study and a registry-based study

van den Berg HM, Mancuso ME, Königs C, D’Oiron R, Platokouki H, Mikkelsen TS, Motwani J, Nolan B, Santagostino E.

ITI Treatment is not First-Choice Treatment in Children with Hemophilia A and Low-Responding Inhibitors: Evidence from a PedNet Study

Male C, Andersson NG, Rafowicz A, Liesner R, Kurnik K, Fischer K, Platokouki H, Santagostino E, Chambost H, Nolan, B, Königs C, Kenet G, Ljung R, van den Berg HM.

Inhibitor Incidence In An Unselected Cohort Of Previously Untreated Patients With Severe Haemophilia B: A PedNet Study


van den Berg HM, Fischer K, Carcao M, Chambost H, Kenet G, Kurnik K, Königs C, Male C, Santagostino E, Ljung R.

Timing of inhibitor development in >1000 previously untreated patients with severe hemophilia A

Volkers P, Hanschmann KM, Calvez T, Chambost H, Collins P, Demiguel V, Hart DP, Hay CRM, Goudemand J, Ljung R, Palmer BP, Santagostino E, van Hardeveld EM, van den Berg HM, Keller-Stanislawski B

Recombinant factor VIII products and inhibitor development in previously untreated patients with severe haemophilia A: Combined analysis of three studies

Andersson NG, Chalmers EA, Kenet G, Ljung R, Mäkipernaa A, Chambost H

Mode of delivery in haemophilia: Vaginal delivery and cesarean section carry similar risk for intracranial hemorrhages and major bleeds


Keipert C, Jonker CJ, van den Berg HM, Hilger, A

Clinical trials and registries in haemophilia: Opponents or collaborators? Comparison of PUP data derived from different data sources


Mancuso ME, Fischer K, Santagostino E, Oldenburg J, Platokouki H, Könings C, Escuriola-Ettingshausen C, Rivard GE, Cid AR, Carcao M, Ljung R, Petrini P, Altisent C, Kenet G, Liesner R, Kurnik K, Auerswald G, Chambost H, Mäkipernaa A, Molinari AC, Williams M, van den Berg HM

PedNet (REMAIN) Study Group
Risk Factors for the Progression from Low to High Titres in 260 Children with Severe Haemophilia A and Newly Developed Inhibitors

Platokouki H, Fischer K, Gouw SC, Rafowicz A, Carcao M, Kenet G, Liesner R, Kurnik, K, Rivard GE, van den Berg HM

Vaccinations are not associated with inhibitor development in boys with severe haemophilia A.

Andersson NG, Auerswald G, Barnes C, Carcao M, Dunn AL, Fijnvandraat K, Hoffmann M, Kavakli K, Kenet G, Kobelt R, Kurnik K, Liesner R, Mäkipernaa A, Manco-Johnson MK, Mancuso ME, Molinari AC, Nolan B, Perez Garrido R, Petrini P, Platokouki HE, Shapiro AD, Wu R, Ljung R

Intracranial haemorrhage in children and adolescents with severe haemophilia A or B – the impact of prophylactic treatment.

Khair K, Ranta S, Thomas A, Lindvall K

PedNet study group.
The impact of clinical practice on the outcome of central venous access devices in children with haemophilia.


Hashemi SM, Fischer K, Moons KG, van den Berg HM

PedNet study group.
Validation of the prediction model for inhibitor development in PUPS with severe haemophilia A.


van den Berg HM, Hashemi SM, Fischer K, Petrini P, Ljung R, Rafowicz A, Carcao M, Auerswald G, Kurnik K, Kenet G, Santagostino E

PedNet study group.
Increased inhibitor incidence in sever haemophilia A since 1990 attributable to more low titre inhibitors.

Hashemi SM, Fischer K, Moons KG, van den Berg HM

Improved prediction of inhibitor development in previously untreated patients with severe haemophilia A.

Nijdam A, Kurnik K, Liesner R, Ljung R, Nolan B, Petrini P, Fischer K

PedNet study group.
How to achieve full prophylaxis in young boys with severe haemophilia A: different regimens and their effect on early bleeding and venous access


Nijdam A, Altisent C, Carcao MD, Cid AR, Claeyssens-Donadel S, Kurnik K, Ljung R, Nolan B, Petrini P, Platokouki H, Rafowicz A, Thomas AE, Fischer K

Bleeding before prophylaxis in severe hemophilia: paradigm shift over two decades.

Clausen N, Petrini P, Claeyssens-Donadel S, Gouw SC, Liesner R

PedNet and Research Of Determitants of INhibitor Development (RODIN) study group
Similar bleeding phenotype in young children with hemophilia A or B: a cohort study

Fischer K, Ljung R, Platokouki H, Liesner R, Claeyssens -Donadel S, Smink E, van den Berg HM.

Prospective observational cohort studies for studying rare
diseases: the European PedNet Haemophilia Registry


van den Berg HM, Gouw SC, van der Bom JG.

PedNet and Research of Determinants of Inhibitor development (RODIN) Study Group.
Factor VIII products and inhibitors in severe hemophilia A.
N Engl J Med. 2013; 368 :1457.

Gouw SC, van den Berg HM, Fischer K, Auerswald G, Carcao M, Chalmers E, Chambost H, Kurnik K, Liesner R, Petrini P, Platokouki H, Altisent C, Oldenburg J, Nolan B, Garrido RP, Mancuso ME, Rafowicz A, Williams M, Clausen N, Middelburg RA, Ljung R, van der Bom JG

PedNet and Research of Determinants of Inhibitor development (RODIN) Study Group.
Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study.
Blood 2013; 16: 4046-55.

Carcao MD, van den Berg HM, Ljung R, Mancuso ME

PedNet and the Rodin Study Group. PedNet and Research of Determinants of Inhibitor development (RODIN) Study Group.
Correlation between phenotype and genotype in a large unselected cohort of children with severe hemophilia A.
Blood 2013; 10: 3946-52.

Gouw SC, van der Bom JG, Ljung R, Escuriola C, Cid AR, Claeyssens-Donadel S, van Geet C, Kenet G, Mäkipernaa A, Molinari AC, Muntean W, Kobelt R, Rivard G, Santagostino E, Thomas A, van den Berg HM

PedNet and RODIN Study Group.
Factor VIII products and inhibitor development in severe hemophilia A.
N Engl J Med 2013 ;368: 231-9.


Donadel-Claeyssens S.

Current co-ordinated activities of the PEDNET (European Paediatric Network for Haemophilia Management)
Haemophilia 2006 Mar;12(2):124-7.

Chambost H, Ljung R.

Pednet Group Changing pattern of care of boys with haemophilia in western European centres
Haemophilia 2005 Mar;11(2):92-9.

Hill F, Ljung R.

Third and fourth workshops of the European paediatric network for haemophilia Management.

Haemophilia 2003, 9, 223-228.

Ljung RCR, Aronis-Vournas S, Kurnik-Auberger K, 
Van den Berg HM, Chambost H, Claeyssens S et al.

Treatment of children with haemophilia in Europe: 
a survey of 20 centres in 16 countries.

Haemophilia 2000;6:619-24.

Ljung R.

Second workshop of the European Paediatric Network for Haemophilia Management 17-19 September 1998 in Vitznau/Switzerland.

Haemophilia 1999, 5, 286-291.